Immunology and Microbiology
Adoptive Immunity
11%
Agonist
8%
Antigen Specificity
11%
Arm
10%
B Cell
8%
Cancer Cell
11%
Cancer Immunotherapy
23%
Cancer Vaccine
36%
CD4
12%
CD8
13%
Cell Infiltration
9%
Colon
8%
Cyclophosphamide
19%
Cytokine
17%
Cytotoxic T-Cell
43%
Dendritic Cell
12%
FVB/N Mouse
7%
Granulocyte Macrophage Colony-Stimulating Factor
38%
Immune Response
51%
Immune System
17%
Immune Tolerance
9%
Immunocompetent Cell
16%
Immunosuppressive Drug
14%
Immunotherapy
82%
Lymph Node
7%
Mesothelin
14%
Monoclonal Antibody
14%
Monospecific Antibody
15%
Mouse
43%
Mouse Model
8%
Myeloid
9%
Neoantigen
13%
Nivolumab
8%
Overall Survival
14%
Pancreas
17%
Programmed Death-Ligand 1
14%
Regulatory T Cell
15%
T Cell
74%
T Cell Receptor
8%
T-Helper Cell
11%
Transgenic Mouse
8%
Tumor Antigen
29%
Tumor Cell
33%
Tumor Cell Vaccine
10%
Tumor Immunology
8%
Tumor Vaccine
29%
Vaccination Policy
26%
Vaccine Efficacy
100%
Vaccine Therapy
7%
Whole Cell
17%
Medicine and Dentistry
Arm
13%
Biological Marker
16%
Breast Cancer
10%
Breast Tumor
8%
Cancer Cell
8%
Cancer Immunotherapy
17%
Cancer Research
7%
Cancer Therapy
9%
Cancer Vaccine
19%
Carcinoma
7%
CD8 Antigen
9%
Cell Line
9%
Cellular Infiltration
8%
Clinical Trial
19%
Colorectal Cancer
10%
Cyclophosphamide
9%
Cytokine
8%
Cytotoxic T-Cell
16%
Disease
17%
Granulocyte Macrophage Colony Stimulating Factor
20%
Hepatocellular Carcinoma
16%
Immune Response
19%
Immunotherapy
54%
Ipilimumab
11%
Lymphocyte
7%
Malignant Neoplasm
51%
Mesothelin
16%
Metastatic Carcinoma
13%
Monoclonal Antibody
10%
Neoplasm
86%
Nivolumab
11%
Oncology
8%
Overall Survival
12%
Pancreas Adenocarcinoma
74%
Pancreas Cancer
78%
Pancreas Tumor
19%
Personalized Medicine
7%
Programmed Death-Ligand 1
11%
Recurrent Disease
10%
Regulatory T Cell
7%
Specific Tumor
10%
Stroma
10%
Surgery
11%
T Cell
39%
T-Cell Response
8%
Tumor Antigen
13%
Tumor Cell
14%
Tumor Microenvironment
32%
Tumor Vaccine
18%
Whole Cell
10%
Keyphrases
Allogeneic
21%
Anti-tumor Response
9%
Antigen-specific
8%
Antitumor Immune Response
18%
Cancer Cells
8%
Cancer Immunotherapy
16%
Cancer Treatment
11%
Cancer Vaccine
22%
CD8+ T Cells
19%
Chemotherapy
12%
Clinical Response
10%
Clinical Trials
16%
Colorectal Cancer
9%
Cyclophosphamide
15%
Granulocyte Colony-stimulating Factor (G-CSF)
29%
Hepatocellular Carcinoma
8%
Human Epidermal Growth Factor Receptor 2 (HER2)
14%
Immune Activation
9%
Immune Checkpoint Inhibitors
9%
Immune Regulation
8%
Immune Response
10%
Immune Tolerance
7%
In Cancer
11%
Ipilimumab
8%
Mesothelin
9%
Metastasis
10%
Metastatic Pancreatic Ductal Adenocarcinoma
10%
Monoclonal Antibody
8%
Neoadjuvant
10%
Neoantigen
11%
Nivolumab
11%
Overall Survival
16%
Pancreas
10%
Pancreatic Adenocarcinoma
22%
Pancreatic Cancer
48%
Pancreatic Ductal Adenocarcinoma
37%
Pancreatic Tumor
18%
Patients with Cancer
8%
Programmed Death-ligand 1 (PD-L1)
12%
T Cell Activation
9%
T Cells
21%
Therapeutic Vaccine
37%
Tumor
57%
Tumor Antigen
19%
Tumor Cells
19%
Tumor Growth
7%
Tumor Immunity
21%
Tumor Microenvironment
29%
Vaccination
10%
Whole-cell Vaccine
7%